UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dual pools of actin at presynaptic terminals

Journal of neurophysiology, 2012-06, Vol.107 (12), p.3479-3492

2012

Volltextzugriff (PDF)

Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry

The Journal of dermatological treatment, 2024-12, Vol.35 (1), p.2287401-2287401

2024

Volltextzugriff (PDF)

Kalirin-7 Controls Activity-Dependent Structural and Functional Plasticity of Dendritic Spines

Neuron (Cambridge, Mass.), 2007-11, Vol.56 (4), p.640-656

2007

Volltextzugriff (PDF)

Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders

The Journal of dermatological treatment, 2022-10, Vol.33 (7), p.2991-2996

2022

Volltextzugriff (PDF)

Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

The Journal of dermatological treatment, 2024-12, Vol.35 (1), p.2342383-2342383

2024

Volltextzugriff (PDF)

Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States

The Journal of dermatological treatment, 2023-12, Vol.34 (1), p.2200869-2200869

2023

Volltextzugriff (PDF)

Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes

Proceedings of the National Academy of Sciences - PNAS, 2009-08, Vol.106 (31), p.13058-13063

2009

Volltextzugriff (PDF)

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial

Rheumatology and therapy., 2024-06, Vol.11 (3), p.617-632

2024

Volltextzugriff (PDF)

G Protein βγ-Subunits Activated by Serotonin Mediate Presynaptic Inhibition by Regulating Vesicle Fusion Properties

Proceedings of the National Academy of Sciences - PNAS, 2006-03, Vol.103 (11), p.4281-4286

2006

Volltextzugriff (PDF)

54001 Efficacy of Risankizumab for Moderate-to-Severe Plaque Psoriasis Through 304 Weeks: Subgroup Analysis by Baseline Demographics and Disease Characteristics From the LIMMitless Trial

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB37-AB37

2024

Volltextzugriff (PDF)

Location and function of vesicle clusters, active zones and Ca2+ channels in the lamprey presynaptic terminal

The Journal of physiology, 2005-11, Vol.569 (1), p.119-135

2005

Volltextzugriff (PDF)

43944 Improvements in Manifestations of Active Psoriatic Arthritis With Risankizumab Treatment After Intolerance or Inadequate Response to Prior Biologic Therapy: Subgroup Analyses From the KEEPsAKE 2 Trial

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB179-AB179

2023

Volltextzugriff (PDF)

44022 Long-Term Efficacy of Continuous Risankizumab in Psoriasis by Body Region: An Updated Integrated Analysis From the LIMMitless Open-Label Extension Study

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB189-AB189

2023

Volltextzugriff (PDF)

44102 Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB82-AB82

2023

Volltextzugriff (PDF)

44134 Long-Term Improvement in Difficult-To-Treat Areas and Quality of Life in Patients with Psoriasis Up to 204 Weeks Post Switch From Ustekinumab To Risankizumab

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB190-AB190

2023

Volltextzugriff (PDF)

51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB59-AB59

2024

Volltextzugriff (PDF)

43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB189-AB189

2023

Volltextzugriff (PDF)

44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB62-AB62

2023

Volltextzugriff (PDF)

Real-World Switch Rates for Patients With Psoriasis Initiating Risankizumab Stratified by Body Mass Index

Skin (Milwood, N.Y.), 2023-11, Vol.7 (6), p.s248

2023

Volltextzugriff (PDF)

Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry

Journal of the American Academy of Dermatology, 2024-01, Vol.90 (1), p.82-90

2024

Volltextzugriff (PDF)

34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB200-AB200

2022

Volltextzugriff (PDF)

Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)

Journal of the European Academy of Dermatology and Venereology, 2024-05, Vol.38 (5), p.864-872

2024

Volltextzugriff (PDF)

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)

British journal of dermatology (1951), 2023-10, Vol.189 (5), p.540-552

2023

Volltextzugriff (PDF)

Maintenance of Response to Risankizumab in Patients With Psoriatic Arthritis: A 3-year Analysis of the KEEPsAKE 1 and 2 Trials

Skin (Milwood, N.Y.), 2023-11, Vol.7 (6), p.s249

2023

Volltextzugriff (PDF)

Epac2 induces synapse remodeling and depression and its disease-associated forms alter spines

Nature neuroscience, 2009-10, Vol.12 (10), p.1275-1284

2009

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(35)
Dissertationen
(1)

Sprache

Englisch
(36)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(15)
Humans
(9)
Animals
(8)
Dermatology
(8)
Neurosciences
(7)
Neurosciences & Neurology
(6)
Psoriasis - Drug Therapy
(6)
Risankizumab
(5)
Severity Of Illness Index
(5)
Treatment Outcome
(5)
Adult
(4)
Cells, Cultured
(4)
Neurons
(4)
Psoriasis
(4)
Rats
(4)
Synaptic Transmission - Physiology
(4)
Guanine Nucleotide Exchange Factors - Physiology
(3)
Memory
(3)
Presynaptic Terminals - Physiology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Dual pools of actin at presynaptic terminals

Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry

Kalirin-7 Controls Activity-Dependent Structural and Functional Plasticity of Dendritic Spines

Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders

Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States

Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial

G Protein βγ-Subunits Activated by Serotonin Mediate Presynaptic Inhibition by Regulating Vesicle Fusion Properties

54001 Efficacy of Risankizumab for Moderate-to-Severe Plaque Psoriasis Through 304 Weeks: Subgroup Analysis by Baseline Demographics and Disease Characteristics From the LIMMitless Trial

Location and function of vesicle clusters, active zones and Ca2+ channels in the lamprey presynaptic terminal

43944 Improvements in Manifestations of Active Psoriatic Arthritis With Risankizumab Treatment After Intolerance or Inadequate Response to Prior Biologic Therapy: Subgroup Analyses From the KEEPsAKE 2 Trial

44022 Long-Term Efficacy of Continuous Risankizumab in Psoriasis by Body Region: An Updated Integrated Analysis From the LIMMitless Open-Label Extension Study

44102 Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments

44134 Long-Term Improvement in Difficult-To-Treat Areas and Quality of Life in Patients with Psoriasis Up to 204 Weeks Post Switch From Ustekinumab To Risankizumab

51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry

43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

Real-World Switch Rates for Patients With Psoriasis Initiating Risankizumab Stratified by Body Mass Index

Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry

34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry

Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)

Maintenance of Response to Risankizumab in Patients With Psoriatic Arthritis: A 3-year Analysis of the KEEPsAKE 1 and 2 Trials

Epac2 induces synapse remodeling and depression and its disease-associated forms alter spines

Suchergebnisse filtern